Oakmark Global Select Fund (Investor Class) Underperforms with 2.91% Return in Q4 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Performance Analysis: The Oakmark Global Select Fund (Investor Class) reported a return of 2.91% in Q4 2025, underperforming the MSCI World Index's 3.12%, indicating relative weakness that may affect investor confidence.
- New Investment Position: During Q4 2025, the fund added a position in Sanofi (SNY), signaling optimism in the pharmaceutical sector and aiming to enhance future returns through a diversified portfolio.
- Exit Strategy: The fund exited its positions in Mercedes-Benz Group (MBGAF) and Roche Holding (RHHBY) in Q4 2025, reflecting a shift in outlook on these companies and potentially optimizing the overall performance of the investment portfolio.
- Market Environment Impact: Given the backdrop of global economic volatility, the underperformance of the Oakmark Global Select Fund may prompt management to reassess investment strategies to adapt to market changes and improve future returns.
Analyst Views on SNY
Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 78.52 USD with a low forecast of 57.00 USD and a high forecast of 116.57 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 47.470
Low
57.00
Averages
78.52
High
116.57
Current: 47.470
Low
57.00
Averages
78.52
High
116.57
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
